New Zealand markets closed

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8400-0.0400 (-1.39%)
At close: 04:00PM EDT
2.8600 +0.02 (+0.70%)
After hours: 07:37PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 193.18M
Enterprise value -173.95M
Trailing P/E 4.07
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.52
Price/book (mrq)0.45
Enterprise value/revenue -0.46
Enterprise value/EBITDA -4.36

Trading information

Stock price history

Beta (5Y monthly) -0.66
52-week change 3-90.32%
S&P500 52-week change 327.86%
52-week high 331.7700
52-week low 32.6700
50-day moving average 312.4258
200-day moving average 317.0009

Share statistics

Avg vol (3-month) 32.96M
Avg vol (10-day) 32.7M
Shares outstanding 567.78M
Implied shares outstanding 667.78M
Float 850.94M
% held by insiders 114.24%
% held by institutions 1104.77%
Shares short (15 Mar 2024) 45.09M
Short ratio (15 Mar 2024) 40.84
Short % of float (15 Mar 2024) 410.01%
Short % of shares outstanding (15 Mar 2024) 47.51%
Shares short (prior month 15 Feb 2024) 44.98M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 12.94%
Operating margin (ttm)1.78%

Management effectiveness

Return on assets (ttm)5.34%
Return on equity (ttm)12.73%

Income statement

Revenue (ttm)380.79M
Revenue per share (ttm)5.66
Quarterly revenue growth (yoy)395.50%
Gross profit (ttm)N/A
EBITDA 39.89M
Net income avi to common (ttm)49.27M
Diluted EPS (ttm)0.7000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)371.36M
Total cash per share (mrq)5.48
Total debt (mrq)4.24M
Total debt/equity (mrq)0.98%
Current ratio (mrq)5.66
Book value per share (mrq)6.52

Cash flow statement

Operating cash flow (ttm)11.92M
Levered free cash flow (ttm)38.36M